Actively Recruiting
Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
Led by Chinese University of Hong Kong · Updated on 2025-06-22
474
Participants Needed
1
Research Sites
367 weeks
Total Duration
On this page
Sponsors
C
Chinese University of Hong Kong
Lead Sponsor
S
Singapore General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or the grey zone of Baveno VII criteria. The main question it aims to answer is: Does carvedilol reduce hepatic decompensation and mortality in these patients despite the absence of varices needing treatment. Researchers will compare carvedilol to no carvedilol to see if carvedilol can prevent hepatic decompensation and mortality. Participants will either take carvedilol or not taking carvedilol for 5 years with regular clinic visit for checkups and investigations, including blood tests, ultrasonography of the liver, upper gastrointestinal endoscopy, transient elastography.
CONDITIONS
Official Title
Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Established diagnosis of chronic liver disease from alcohol-related liver disease, chronic hepatitis B, chronic hepatitis C, or metabolic dysfunction-associated steatotic liver disease (both non-obese and obese)
- Classified in high-risk grey zone or with clinically significant portal hypertension based on Baveno VII criteria or ANTICIPATE-NASH model within 6 months before screening
- Underwent liver stiffness measurement (LSM) and platelet count assessment to determine eligibility
You will not qualify if you...
- Presence of high-risk varices such as moderate to large oesophageal varices or varices with red wale sign
- Current or recent use (within 6 months) of non-selective beta-blockers
- Contraindication to non-selective beta-blockers including heart block, bradycardia, low systolic blood pressure, asthma, poorly controlled chronic obstructive pulmonary disease, or peripheral vascular disease
- Current or recent use (within 6 months) of nitrated drugs except sublingual nitrates
- Contraindication to upper gastrointestinal endoscopy
- Current or history of decompensated liver cirrhosis or prior decompensation events
- Current or history of hepatocellular carcinoma
- Current or history of portal vein thrombosis
- Presence of transjugular intrahepatic portosystemic shunt (TIPS)
- Prior liver transplantation
- Serious medical illness with life expectancy less than 6 months
- Pregnancy
- Unable or unwilling to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
A
Angel Chim, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here